![]() Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. Year ago and is now widely available in the US, the EU and several otherĬountries worldwide,” said Professor Jörg Kreuzer, Vice President “Praxbind ® received its first approval in the US nearly a This Smart News Release features multimedia. The actual usage of the reversal agent in the clinical practice setting. Data captured in RE-VECTO will help better understand May be used can vary greatly, ranging from a severe car accident to a 1,2 The emergency situations in which Praxbind ® ![]() In rare critical care situations such as prior to emergency surgery orĪn urgent intervention, or in cases of life-threatening or uncontrolledīleeding. Is approved to reverse the anticoagulant effects of Pradaxa ® Praxbind ® (idarucizumab), the specific reversal agent for Boehringer Ingelheim today announces its global RE-VECTO program for
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |